Loading…
Loading the latest PSX data…
Loading the latest PSX data…
Hoechst Pakistan Limited (HPL), GlaxoSmithKline Pakistan Limited (GLAXO), Abbott Laboratories (Pakistan) Limited (ABOT): performance, valuation, growth, risk and danioPSX score, side by side.
Add a stock
Growth of Rs 100 from 2025-11-11
Daily closes from PSX end-of-day files, adjusted for bonus shares, right issues and splits (not for cash dividends). KSE-100: official closes where available, otherwise rebuilt from its constituents.
| Measure | HPLPharmaceuticals | GLAXOPharmaceuticals | ABOTPharmaceuticals |
|---|---|---|---|
| danioPSX score | – | 87 | 81 |
| Price and size | |||
| Price | Rs 4,017.76 | Rs 333.18 | Rs 1,005.70 |
| Today | +0.53% | −1.89% | +0.18% |
| Market cap | Rs 38.8bn | Rs 106.1bn | Rs 98.5bn |
| Traded per day | Rs 1m | Rs 51m | Rs 15m |
| Valuation and dividends | |||
| P/E | 11.1 | 9.7 | 10.6 |
| Dividend yield | 6.9% | 6.1% | 4.4% |
| EPS (last year) | Rs 301.67 | Rs 31.48 | Rs 81.37 |
| Business | |||
| EPS growth | +56.7% | +53.4% | +52.2% |
| Sales growth | +15.6% | +7.7% | +10.6% |
| Net margin | 9.4% | 15.2% | 10.6% |
| Returns | |||
| 1 month | +0.2% | +6.6% | +6.5% |
| 3 months | +2.2% | −2.9% | +12.1% |
| 1 year | −2.7% | −15.4% | −7.6% |
| vs KSE-100, 1 year | -15.3 pts | -26.3 pts | -18.5 pts |
| Trend and risk | |||
| 52-week position | 32% | 24% | 41% |
| RSI 14 | 55 | 57 | 67 |
| RS rank | 55 | 39 | 68 |
| Volatility | 23% | 34% | 30% |
| Beta | 0.23 | 1.06 | 0.77 |
| danioPSX score | |||
| Value | – | 69 | 61 |
| Quality | – | 81 | 74 |
| Dividend | – | 64 | 34 |
| Momentum | – | 34 | 61 |
| Safety | – | 80 | 76 |
| Shariah-compliant | Yes | Yes | Yes |
Bold marks the best value in each row where higher (or, for P/E and volatility, lower) is clearly better.
A comparison of published numbers, not a recommendation. Share this page: the address holds the stocks. Find more stocks with the screener